221201-28-1

Basic information

• Product Name: 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(1-piperidinyl)phenyl]-, (5S)-
• CAS NO: 221201-28-1
• Molecular Formula: C15H20FN3O2
• Molecular Weight: 293.341
• Mol File: 221201-28-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(1-piperidinyl)phenyl]-, (5S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(1-piperidinyl)phenyl]-, (5S)-(221201-28-1)
• EPA Substance Registry System: 2-Oxazolidinone, 5-(aminomethyl)-3-[3-fluoro-4-(1-piperidinyl)phenyl]-, (5S)-(221201-28-1)

Safety Data

• Hazardous Substances Data: 221201-28-1(Hazardous Substances Data)

Upstream product

• 556801-60-6 Methanesulfonic acid (R)-3-(3-fluoro-4-piperidin-1-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl ester 
• 172967-06-5 (R)-3-(3-Fluoro-4-piperidin-1-yl-phenyl)-5-hydroxymethyl-oxazolidin-2-one 
• 172967-04-3 1-(2-fluoro-4-nitrophenyl)piperidine 
• 85983-56-8 3-fluoro-4-(piperidin-1-yl)aniline 
• 172967-08-7 (R)-5-Azidomethyl-3-(3-fluoro-4-piperidin-1-yl-phenyl)-oxazolidin-2-one 

Downstream Products

• 221202-55-7 1-Benzoyl-3-[(S)-3-(3-fluoro-4-piperidin-1-yl-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-thiourea 

Relevant articles and documents

A method for the prevention or treatment of mycobacterial diseases

Disclosed in the present invention is a drug for preventing or treating mycobacterial diseases. In particular, disclosed is the use of a compound represented by the following general formula (I) or pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs thereof in preparing drugs for preventing or treating mycobacterial diseases, providing a new way for the prevention and treatment of tuberculosis and the like.

Structure-activity relationship (SAR) studies on oxazolidinone antibacterial agents. 2.1) Relationship between lipophilicity and antibacterial activity in 5-thiocarbonyl oxazolidinones

5-Thiourea and 5-dithiocarbamate oxazolidinones were synthesized as a continuation of research on 5-thiocarbonyl oxazolidinone antibacterial agents considering the hydrophobic parameters of the molecule. The structure-activity relationship (SAR) study revealed that the antibacterial activity on 5-thiocarbonyl oxazolidinones was significantly affected by the lipophilicity, especially the calculated log P value and the balance between 5-hydrophilic (or hydrophobic) substituent and hydrophobic (or hydrophilic) substituents on the benzene ring. Some of 5-thiocarbonyl oxazolidinones were found to have good in vitro antibacterial activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).